Sarepta Therapeutics
(SRPT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,103,010 | 428,430 | 966,777 | 2,115,869 | 1,502,648 |
| Marketable Securities | 251,782 | 1,247,820 | 1,022,597 | 0 | 435,923 |
| Receivables | 601,988 | 400,327 | 214,628 | 152,990 | 101,340 |
| Inventories | 749,960 | 322,859 | 203,968 | 186,212 | 231,961 |
| Other current assets | 366,723 | 179,895 | 149,891 | 149,028 | 213,324 |
| TOTAL | $3,073,463 | $2,579,331 | $2,557,861 | $2,604,099 | $2,485,196 |
| Non-Current Assets | |||||
| PPE Net | 340,336 | 227,154 | 180,037 | 191,156 | 190,430 |
| Investments And Advances | 133,163 | 0 | 0 | 0 | 0 |
| Intangibles | 0 | 0 | 0 | 14,239 | 13,628 |
| Other Non-Current Assets | 416,211 | 458,091 | 390,468 | 338,480 | 295,464 |
| TOTAL | $889,710 | $685,245 | $570,505 | $543,875 | $499,522 |
| Total Assets | $3,963,173 | $3,264,576 | $3,128,366 | $3,147,974 | $2,984,718 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 105,483 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 214,442 | 164,918 | 95,875 | 76,741 | 111,090 |
| Accrued Expenses | 373,513 | 314,997 | 418,996 | 271,697 | 193,553 |
| Other current liabilities | 13,473 | 17,845 | N/A | 15,051 | 22,139 |
| TOTAL | $731,684 | $653,659 | $619,604 | $452,733 | $416,026 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,137,124 | 1,132,515 | 1,544,292 | 1,096,876 | 992,493 |
| Deferred Revenues | 130,256 | 50,416 | 89,244 | 89,244 | 89,244 |
| Other Non-Current Liabilities | 241,623 | 182,065 | 94,520 | 96,112 | 150,952 |
| TOTAL | $1,703,747 | $1,751,580 | $2,123,812 | $1,767,232 | $1,806,933 |
| Total Liabilities | $2,435,431 | $2,405,239 | $2,743,416 | $2,219,965 | $2,222,959 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 97,032 | 93,855 | 87,982 | 87,150 | 79,421 |
| Common Shares | 10 | 9 | 9 | 9 | 8 |
| Retained earnings | -4,210,974 | -4,446,213 | -3,910,236 | -3,206,748 | -2,848,129 |
| Other shareholders' equity | -218 | 918 | -1,664 | -20 | 3 |
| TOTAL | $1,527,742 | $859,337 | $384,950 | $928,009 | $761,759 |
| Total Liabilities And Equity | $3,963,173 | $3,264,576 | $3,128,366 | $3,147,974 | $2,984,718 |